Pharmacokinetic—Pharmacodynamic Modeling of Tumor Targeted Drug Delivery Using Nano-Engineered Mesenchymal Stem Cells

Nano-engineered mesenchymal stem cells (nano-MSCs) are promising targeted drug delivery platforms for treating solid tumors. MSCs engineered with paclitaxel (PTX) loaded poly(lactide-co-glycolide) (PLGA) nanoparticles (NPs) are efficacious in treating lung and ovarian tumors in mouse models. The qua...

Full description

Bibliographic Details
Main Authors: Shen Cheng, Susheel Kumar Nethi, Mahmoud Al-Kofahi, Swayam Prabha
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Pharmaceutics
Subjects:
Online Access:https://www.mdpi.com/1999-4923/13/1/92
_version_ 1827601743230271488
author Shen Cheng
Susheel Kumar Nethi
Mahmoud Al-Kofahi
Swayam Prabha
author_facet Shen Cheng
Susheel Kumar Nethi
Mahmoud Al-Kofahi
Swayam Prabha
author_sort Shen Cheng
collection DOAJ
description Nano-engineered mesenchymal stem cells (nano-MSCs) are promising targeted drug delivery platforms for treating solid tumors. MSCs engineered with paclitaxel (PTX) loaded poly(lactide-co-glycolide) (PLGA) nanoparticles (NPs) are efficacious in treating lung and ovarian tumors in mouse models. The quantitative description of pharmacokinetics (PK) and pharmacodynamics (PD) of nano-MSCs is crucial for optimizing their therapeutic efficacy and clinical translatability. However, successful translation of nano-MSCs is challenging due to their complex composition and physiological mechanisms regulating their pharmacokinetic-pharmacodynamic relationship (PK–PD). Therefore, in this study, a mechanism-based preclinical PK–PD model was developed to characterize the PK–PD relationship of nano-MSCs in orthotopic A549 human lung tumors in SCID Beige mice. The developed model leveraged literature information on diffusivity and permeability of PTX and PLGA NPs, PTX release from PLGA NPs, exocytosis of NPs from MSCs as well as PK and PD profiles of nano-MSCs from previous in vitro and in vivo studies. The developed PK–PD model closely captured the reported tumor growth in animals receiving no treatment, PTX solution, PTX-PLGA NPs and nano-MSCs. Model simulations suggest that increasing the dosage of nano-MSCs and/or reducing the rate of PTX-PLGA NPs exocytosis from MSCs could result in improved anti-tumor efficacy in preclinical settings.
first_indexed 2024-03-09T05:03:18Z
format Article
id doaj.art-2b45cb59eb8742f8899d2f374f45ae2f
institution Directory Open Access Journal
issn 1999-4923
language English
last_indexed 2024-03-09T05:03:18Z
publishDate 2021-01-01
publisher MDPI AG
record_format Article
series Pharmaceutics
spelling doaj.art-2b45cb59eb8742f8899d2f374f45ae2f2023-12-03T12:57:42ZengMDPI AGPharmaceutics1999-49232021-01-011319210.3390/pharmaceutics13010092Pharmacokinetic—Pharmacodynamic Modeling of Tumor Targeted Drug Delivery Using Nano-Engineered Mesenchymal Stem CellsShen Cheng0Susheel Kumar Nethi1Mahmoud Al-Kofahi2Swayam Prabha3Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USAFels Institute for Cancer Research & Molecular Biology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USADepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USADepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USANano-engineered mesenchymal stem cells (nano-MSCs) are promising targeted drug delivery platforms for treating solid tumors. MSCs engineered with paclitaxel (PTX) loaded poly(lactide-co-glycolide) (PLGA) nanoparticles (NPs) are efficacious in treating lung and ovarian tumors in mouse models. The quantitative description of pharmacokinetics (PK) and pharmacodynamics (PD) of nano-MSCs is crucial for optimizing their therapeutic efficacy and clinical translatability. However, successful translation of nano-MSCs is challenging due to their complex composition and physiological mechanisms regulating their pharmacokinetic-pharmacodynamic relationship (PK–PD). Therefore, in this study, a mechanism-based preclinical PK–PD model was developed to characterize the PK–PD relationship of nano-MSCs in orthotopic A549 human lung tumors in SCID Beige mice. The developed model leveraged literature information on diffusivity and permeability of PTX and PLGA NPs, PTX release from PLGA NPs, exocytosis of NPs from MSCs as well as PK and PD profiles of nano-MSCs from previous in vitro and in vivo studies. The developed PK–PD model closely captured the reported tumor growth in animals receiving no treatment, PTX solution, PTX-PLGA NPs and nano-MSCs. Model simulations suggest that increasing the dosage of nano-MSCs and/or reducing the rate of PTX-PLGA NPs exocytosis from MSCs could result in improved anti-tumor efficacy in preclinical settings.https://www.mdpi.com/1999-4923/13/1/92mesenchymal stem cellstargeted therapypharmacokinetics and pharmacodynamicsmodeling and simulation
spellingShingle Shen Cheng
Susheel Kumar Nethi
Mahmoud Al-Kofahi
Swayam Prabha
Pharmacokinetic—Pharmacodynamic Modeling of Tumor Targeted Drug Delivery Using Nano-Engineered Mesenchymal Stem Cells
Pharmaceutics
mesenchymal stem cells
targeted therapy
pharmacokinetics and pharmacodynamics
modeling and simulation
title Pharmacokinetic—Pharmacodynamic Modeling of Tumor Targeted Drug Delivery Using Nano-Engineered Mesenchymal Stem Cells
title_full Pharmacokinetic—Pharmacodynamic Modeling of Tumor Targeted Drug Delivery Using Nano-Engineered Mesenchymal Stem Cells
title_fullStr Pharmacokinetic—Pharmacodynamic Modeling of Tumor Targeted Drug Delivery Using Nano-Engineered Mesenchymal Stem Cells
title_full_unstemmed Pharmacokinetic—Pharmacodynamic Modeling of Tumor Targeted Drug Delivery Using Nano-Engineered Mesenchymal Stem Cells
title_short Pharmacokinetic—Pharmacodynamic Modeling of Tumor Targeted Drug Delivery Using Nano-Engineered Mesenchymal Stem Cells
title_sort pharmacokinetic pharmacodynamic modeling of tumor targeted drug delivery using nano engineered mesenchymal stem cells
topic mesenchymal stem cells
targeted therapy
pharmacokinetics and pharmacodynamics
modeling and simulation
url https://www.mdpi.com/1999-4923/13/1/92
work_keys_str_mv AT shencheng pharmacokineticpharmacodynamicmodelingoftumortargeteddrugdeliveryusingnanoengineeredmesenchymalstemcells
AT susheelkumarnethi pharmacokineticpharmacodynamicmodelingoftumortargeteddrugdeliveryusingnanoengineeredmesenchymalstemcells
AT mahmoudalkofahi pharmacokineticpharmacodynamicmodelingoftumortargeteddrugdeliveryusingnanoengineeredmesenchymalstemcells
AT swayamprabha pharmacokineticpharmacodynamicmodelingoftumortargeteddrugdeliveryusingnanoengineeredmesenchymalstemcells